These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1433373)

  • 1. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.
    Stadler WM; Richards JM; Vogelzang NJ
    J Natl Cancer Inst; 1992 Dec; 84(23):1835-6. PubMed ID: 1433373
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
    Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
    J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
    Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma.
    Altundag O; Altundag K; Gunduz E
    J Clin Oncol; 2005 Feb; 23(5):1044; author reply 1044-5. PubMed ID: 15701926
    [No Abstract]   [Full Text] [Related]  

  • 7. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma.
    Kimura M; Tomita Y; Imai T; Saito T; Katagiri A; Ohara-Mikami Y; Matsudo T; Takahashi K
    Cancer; 2001 Oct; 92(8):2072-5. PubMed ID: 11596022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
    Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients.
    O'Byrne KJ; Dobbs N; Harris AL
    Br J Cancer; 2000 Jun; 82(11):1895-6. PubMed ID: 10839310
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma.
    Ljungberg B; Grankvist K; Rasmuson T
    Eur J Cancer; 1997 Oct; 33(11):1794-8. PubMed ID: 9470835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Novara G
    Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
    [No Abstract]   [Full Text] [Related]  

  • 12. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma.
    Wittke F; Hoffmann R; Buer J; Dallmann I; Oevermann K; Sel S; Wandert T; Ganser A; Atzpodien J
    Br J Cancer; 1999 Mar; 79(7-8):1182-4. PubMed ID: 10098756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.
    Wang Y; Zhang Y
    Clin Transl Oncol; 2020 Jun; 22(6):835-843. PubMed ID: 31410730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
    Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
    Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
    Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
    BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma.
    Gu L; Ma X; Xie Y; Li H; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
    Clin Genitourin Cancer; 2017 Jun; 15(3):e369-e377. PubMed ID: 28038932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.